Treatment with CO significantly decreased SOD activity (NAFLD + CO = 91.56 ± 19.42 U/mg protein) compared with NAFLD group (Figure 3(a)). This evidence concerns the gene SOD1 and metabolic dysfunction-associated steatotic liver disease.